These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 23475782)

  • 21. Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization.
    Kuger S; Flentje M; Djuzenova CS
    Radiat Oncol; 2015 Oct; 10():214. PubMed ID: 26498922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines.
    Masuda M; Shimomura M; Kobayashi K; Kojima S; Nakatsura T
    Oncol Rep; 2011 Nov; 26(5):1273-9. PubMed ID: 21725613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations.
    Park YL; Kim HP; Cho YW; Min DW; Cheon SK; Lim YJ; Song SH; Kim SJ; Han SW; Park KJ; Kim TY
    Int J Cancer; 2019 Jan; 144(2):389-401. PubMed ID: 29978469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual-Blocking of PI3K and mTOR Improves Chemotherapeutic Effects on SW620 Human Colorectal Cancer Stem Cells by Inducing Differentiation.
    Kim MJ; Koo JE; Han GY; Kim B; Lee YS; Ahn C; Kim CW
    J Korean Med Sci; 2016 Mar; 31(3):360-70. PubMed ID: 26955235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma.
    Yang F; Qian XJ; Qin W; Deng R; Wu XQ; Qin J; Feng GK; Zhu XF
    PLoS One; 2013; 8(3):e59879. PubMed ID: 23533654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vertical inhibition of PI3K/Akt/mTOR signaling demonstrates in vitro and in vivo anti-fibrotic activity.
    Liang M; Lv J; Chu H; Wang J; Chen X; Zhu X; Xue Y; Guan M; Zou H
    J Dermatol Sci; 2014 Nov; 76(2):104-11. PubMed ID: 25258031
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
    Li H; Jin X; Zhang Z; Xing Y; Kong X
    Cell Biochem Funct; 2013 Jul; 31(5):427-33. PubMed ID: 23086777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blockage of Stat3 enhances the sensitivity of NSCLC cells to PI3K/mTOR inhibition.
    Jin HO; Lee YH; Park JA; Kim JH; Hong SE; Kim HA; Kim EK; Noh WC; Kim BH; Ye SK; Chang YH; Hong SI; Hong YJ; Park IC; Lee JK
    Biochem Biophys Res Commun; 2014 Feb; 444(4):502-8. PubMed ID: 24472538
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate.
    Gobin B; Battaglia S; Lanel R; Chesneau J; Amiaud J; Rédini F; Ory B; Heymann D
    Cancer Lett; 2014 Mar; 344(2):291-8. PubMed ID: 24333720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
    Risberg K; Redalen KR; Sønstevold L; Bjørnetrø T; Sølvernes J; Ree AH
    BMC Cancer; 2016 Jul; 16():531. PubMed ID: 27461218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy.
    Chang Z; Shi G; Jin J; Guo H; Guo X; Luo F; Song Y; Jia X
    Int J Mol Med; 2013 Jun; 31(6):1449-56. PubMed ID: 23588698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NVP-BEZ235, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, prominently enhances radiosensitivity of prostate cancer cell line PC-3.
    Zhu W; Fu W; Hu L
    Cancer Biother Radiopharm; 2013 Nov; 28(9):665-73. PubMed ID: 23768063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual inhibitor of phosphoinositide 3-kinase/mammalian target of rapamycin NVP-BEZ235 effectively inhibits cisplatin-resistant urothelial cancer cell growth through autophagic flux.
    Li JR; Cheng CL; Yang CR; Ou YC; Wu MJ; Ko JL
    Toxicol Lett; 2013 Jul; 220(3):267-76. PubMed ID: 23651616
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer.
    Venkannagari S; Fiskus W; Peth K; Atadja P; Hidalgo M; Maitra A; Bhalla KN
    Oncotarget; 2012 Nov; 3(11):1416-27. PubMed ID: 23232026
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.
    Chapuis N; Tamburini J; Green AS; Vignon C; Bardet V; Neyret A; Pannetier M; Willems L; Park S; Macone A; Maira SM; Ifrah N; Dreyfus F; Herault O; Lacombe C; Mayeux P; Bouscary D
    Clin Cancer Res; 2010 Nov; 16(22):5424-35. PubMed ID: 20884625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells.
    Kim A; Park S; Lee JE; Jang WS; Lee SJ; Kang HJ; Lee SS
    Leuk Res; 2012 Jul; 36(7):912-20. PubMed ID: 22560334
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual PI3K/mTOR Inhibitor BEZ235 combined with BMS-1166 Promoting Apoptosis in Colorectal Cancer.
    Liu X; Xu W; Li L; Zhang Z; Lu M; Xia X
    Int J Med Sci; 2024; 21(10):1814-1823. PubMed ID: 39113885
    [No Abstract]   [Full Text] [Related]  

  • 38. The phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 is effective in inhibiting regrowth of tumour cells after cytotoxic therapy.
    Hernlund E; Olofsson MH; Fayad W; Fryknäs M; Lesiak-Mieczkowska K; Zhang X; Brnjic S; Schmidt V; D'Arcy P; Sjöblom T; De Milito A; Larsson R; Linder S
    Eur J Cancer; 2012 Feb; 48(3):396-406. PubMed ID: 22154651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
    Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
    J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
    Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.